Endocrine-Related Adverse Conditions in Pediatric Patients Treated with Immune Checkpoint Inhibitors: A Position Statement from the Clinical Practice Committee of the European Society for Pediatric Endocrinology.
Christa E Flück, Dulanjalee Kariyawasam, Francesco Ceppi, Shlomit Shalitin, Kanetee Busiah
{"title":"Endocrine-Related Adverse Conditions in Pediatric Patients Treated with Immune Checkpoint Inhibitors: A Position Statement from the Clinical Practice Committee of the European Society for Pediatric Endocrinology.","authors":"Christa E Flück, Dulanjalee Kariyawasam, Francesco Ceppi, Shlomit Shalitin, Kanetee Busiah","doi":"10.1159/000546146","DOIUrl":null,"url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) are new cancer therapies that function either by blocking the interaction between programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) or by inhibiting cytotoxic T-lymphocyte antigen 4 (CTLA-4). The utilization of ICIs has improved outcomes for advanced, relapsed, or refractory malignancies in adults and children. Concerns have been raised due to immune-related adverse events (irAEs). The most frequently observed endocrine irAEs in children and adolescents include adrenal insufficiency, diabetes, thyroid dysfunction, and hypophysitis. The Clinical Practice Committee of the European Society for Pediatric Endocrinology (ESPE) aims to highlight the current knowledge and gaps on ICI irAE on the endocrine system in children and adolescents.</p>","PeriodicalId":13025,"journal":{"name":"Hormone Research in Paediatrics","volume":" ","pages":"1-4"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176352/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone Research in Paediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546146","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Immune checkpoint inhibitors (ICIs) are new cancer therapies that function either by blocking the interaction between programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) or by inhibiting cytotoxic T-lymphocyte antigen 4 (CTLA-4). The utilization of ICIs has improved outcomes for advanced, relapsed, or refractory malignancies in adults and children. Concerns have been raised due to immune-related adverse events (irAEs). The most frequently observed endocrine irAEs in children and adolescents include adrenal insufficiency, diabetes, thyroid dysfunction, and hypophysitis. The Clinical Practice Committee of the European Society for Pediatric Endocrinology (ESPE) aims to highlight the current knowledge and gaps on ICI irAE on the endocrine system in children and adolescents.
期刊介绍：
The mission of ''Hormone Research in Paediatrics'' is to improve the care of children with endocrine disorders by promoting basic and clinical knowledge. The journal facilitates the dissemination of information through original papers, mini reviews, clinical guidelines and papers on novel insights from clinical practice. Periodic editorials from outstanding paediatric endocrinologists address the main published novelties by critically reviewing the major strengths and weaknesses of the studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
